Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore will be presenting at the 16th annual LD Micro Main Event on Wednesday, October 4th at 11:00 PT at the Luxe Sunset Boulevard Hotel in Los Angeles.
The Australian based and globally integrated biopharmaceutical company today released the presentation slides that Lydeamore will be presenting at the prominent three-day investor conference.
Included are anticipated key milestones that the company expects to drive value, including progressing to clinical trials for Travelan, CampETEC and IMM-529.
Immunron is a Melbourne based biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
Its Travelan product is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travellers’ diarrhoea, a digestive tract disorder commonly caused by pathogenic bacteria and the toxins they produce.